Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial-Reference-Cited by-同舟云学术

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Published:2008-07 Issue:9633 Volume:372 Page:117-126
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Eggermont Alexander MM,Suciu Stefan,Santinami Mario,Testori Alessandro,Kruit Wim HJ,Marsden Jeremy,Punt Cornelis JA,Salès François,Gore Martin,MacKie Rona,Kusic Zvonko,Dummer Reinhard,Hauschild Axel,Musat Elena,Spatz Alain,Keilholz Ulrich

Publisher

Elsevier BV

Subject

General Medicine

Reference26 articles.

1. Prognostic factors analysis of 17600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System;Balch;J Clin Oncol,2001

2. European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma;Eggermont;Semin Oncol,2002

3. Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials;Wheatley;Cancer Treat Rev,2003

4. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684;Kirkwood;J Clin Oncol,1996

5. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of Intergroup Trial E1690/S9111/C9190;Kirkwood;J Clin Oncol,2000

Cited by 570 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant therapy for melanoma: past, present, and future;Surgical Oncology;2024-10

2. Advancements in Melanoma Therapies: From Surgery to Immunotherapy;Current Treatment Options in Oncology;2024-07-27

3. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma;JAMA Oncology;2024-05-01

4. Targeting autophagy to counteract neuroinflammation: A novel antidepressant strategy;Pharmacological Research;2024-04

5. Treatment of Stage III Resectable Melanoma—Adjuvant and Neoadjuvant Approaches;The Cancer Journal;2024-03